Hormone Therapy for Cancer: How It Works and Side Effects

Hormone therapy is a cancer treatment that blocks or reduces the hormone signals certain cancers depend on to grow. The two cancers most commonly treated with hormone therapy are hormone receptor-positive (HR+) breast cancer — approximately 75–80% of all breast cancers — and prostate cancer, which virtually always depends on androgens (testosterone and dihydrotestosterone) for growth in its early stages.

The principle is straightforward: if a cancer cell uses a hormone to grow, depriving it of that hormone — or blocking the receptor the hormone activates — starves the cancer of its growth signal. Hormone therapy is distinct from chemotherapy (which kills all rapidly dividing cells), radiation (which targets tissue locally), and targeted therapy (which blocks specific molecular alterations). It is also important not to confuse hormone therapy for cancer with hormone replacement therapy (HRT) used to treat menopause — they work in opposite directions: HRT restores estrogen; breast cancer hormone therapy reduces or blocks estrogen. For an overview of how hormone therapy fits within all cancer treatment approaches, see the cancer treatment guide.

~75% Percentage of all breast cancers that are hormone receptor-positive (HR+) — the largest targetable subset of breast cancer

10 years Duration of adjuvant tamoxifen that reduces breast cancer recurrence by 25% and mortality by 29% vs. 5 years (ATLAS trial, Lancet 2012)

40.4 vs. 18.4 mo Metastasis-free survival with darolutamide vs. placebo for non-metastatic castration-resistant prostate cancer (ARAMIS trial)

96.7% Castration rate with oral relugolix (HERO trial) — with fewer cardiovascular events than standard GnRH agonist leuprolide

How Hormone Therapy Works

Hormone-driven cancer cells express hormone receptors — estrogen receptors (ER), progesterone receptors (PR), or androgen receptors (AR) — that, when activated by the circulating hormone, trigger transcription of genes driving proliferation and survival. Hormone therapy interrupts this signal in three ways:

1. Reduce Hormone Availability

Aromatase inhibitors block estrogen synthesis. GnRH agonists/antagonists suppress testosterone. Oophorectomy or orchiectomy permanently eliminates the primary source.

2. Block the Receptor

Tamoxifen blocks ER in breast tissue. Enzalutamide, bicalutamide, darolutamide, apalutamide block androgen receptor in prostate. The hormone may still be present, but the receptor cannot signal.

3. Degrade the Receptor

SERDs (fulvestrant, elacestrant) bind ER and trigger its degradation via the ubiquitin-proteasome pathway — eliminating the receptor itself. Active even when ESR1 mutations make the receptor ligand-independent.

CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) are molecular targeted drugs — not hormone therapy — but are almost always combined with hormone therapy in HR+/HER2- metastatic breast cancer to overcome endocrine resistance. See the targeted therapy cancer guide for CDK4/6 inhibitor detail.

Hormone Therapy for Breast Cancer

Tamoxifen — The SERM Standard

Tamoxifen competitively binds the estrogen receptor in breast cancer cells, acting as an antagonist that prevents estrogen from activating ER-driven transcription. In bone and uterine tissue, it acts as a partial agonist — preserving bone density but elevating endometrial cancer risk.

Tamoxifen is standard adjuvant endocrine therapy for premenopausal HR+ breast cancer and is also used in postmenopausal women when aromatase inhibitors are contraindicated. Historical standard was 5 years, but the landmark ATLAS trial (Davies C et al., Lancet 2012) changed practice: extending from 5 to 10 years of tamoxifen reduced breast cancer recurrence by 25% and breast cancer mortality by 29% in years 5–14 after diagnosis — and NCCN now recommends 10 years of total endocrine therapy for high-risk HR+ disease.

CYP2D6 and Tamoxifen Efficacy

Tamoxifen requires conversion to its active metabolite endoxifen by the liver enzyme CYP2D6. Poor metabolizers (CYP2D6*4/*4, ~7–10% of the population) have lower endoxifen levels and may derive less benefit. Critically, the SSRIs paroxetine and fluoxetine — commonly used to treat tamoxifen-related hot flashes — are potent CYP2D6 inhibitors that substantially reduce endoxifen concentrations. Use venlafaxine, oxybutynin, or other CYP2D6-neutral agents for hot flashes in patients on tamoxifen.

Tamoxifen side effects: Hot flashes, vaginal discharge, irregular periods, VTE (~2× increased risk), endometrial cancer risk (~2–3× baseline — requires annual gynecologic evaluation and immediate evaluation of abnormal uterine bleeding), mood changes.

Aromatase Inhibitors (AIs)

In postmenopausal women, the primary estrogen source shifts from the ovaries to peripheral tissue (adipose, muscle) where the enzyme aromatase (CYP19A1) converts androgens to estrogens. Aromatase inhibitors block this enzyme, reducing estradiol levels by >90–95%.

Anastrozole (Arimidex): Non-steroidal; reversible. ATAC trial: DFS HR 0.87 vs. tamoxifen; fewer gynecologic side effects
Letrozole (Femara): Non-steroidal; reversible. BIG 1-98: DFS HR 0.82 vs. tamoxifen; most potent estrogen suppression of the three
Exemestane (Aromasin): Steroidal (androstenedione analogue); irreversible; mild androgenic activity

Extended adjuvant AIs: MA.17 trial: 5 years of letrozole after 5 years of tamoxifen further reduces recurrence. NCCN recommends up to 10 years total endocrine therapy for high-risk HR+ breast cancer (5 years tamoxifen → 5 years AI; or 5 years AI → 5 years AI).

AI side effects: Hot flashes, vaginal dryness and atrophic vaginitis, arthralgia and myalgia (“AI arthralgia” — affects 30–40% of women; a leading cause of non-adherence; managed with NSAIDs, vitamin D, exercise, acupuncture), bone density loss (baseline DEXA; bisphosphonate or denosumab 60 mg q6m for significant loss), cardiovascular risk (less endometrial/VTE risk than tamoxifen but no partial agonist bone protection).

Ovarian Function Suppression (OFS)

Aromatase inhibitors only work when estrogen levels are already low. For premenopausal women, ovarian function must be suppressed first to allow AI use. Methods:

GnRH agonists (goserelin, leuprolide, triptorelin): monthly or 3-monthly SC injections; ovarian function recovers after stopping — important for fertility preservation
Surgical oophorectomy: Permanent OFS; appropriate when long-term OFS is required and fertility is not desired

The SOFT/TEXT trials (8-year follow-up Pagani O, ASCO 2019): OFS + exemestane vs. tamoxifen alone for premenopausal HR+ early BC: 8-year DFS 86.8% vs. 83.2% — benefit concentrated in high-risk patients (under 35, post-chemotherapy and still premenopausal, node-positive, Ki67 high). OFS is not required for all premenopausal HR+ patients — lower-risk women may use tamoxifen alone.

Selective Estrogen Receptor Degraders (SERDs)

SERDs bind the estrogen receptor and trigger its degradation through the ubiquitin-proteasome pathway, eliminating the receptor protein. They overcome a critical resistance mechanism: ESR1 mutations — point mutations in the ER ligand-binding domain that arise in ~40% of HR+/HER2- metastatic patients after aromatase inhibitor treatment. ESR1 mutations cause ligand-independent ER activation — the receptor remains constitutively active even without estrogen, rendering AIs (which work by reducing estrogen) ineffective. SERDs bind and degrade the mutant ER directly, regardless of ligand.

Fulvestrant (Faslodex): Pure ER antagonist + degrader; IM injection 500 mg monthly; no partial agonist activity. FALCON trial: PFS 16.6 vs. 13.8 months vs. anastrozole in endocrine-naïve metastatic HR+/HER2-; combined with CDK4/6 inhibitors (MONARCH 2: OS 46.7 vs. 37.3 months; MONALEESA-3)
Elacestrant (Orserdu): First oral SERD (FDA January 2023). EMERALD trial: elacestrant vs. physician’s choice endocrine therapy for ESR1-mutated HR+/HER2- MBC after CDK4/6 inhibitor: PFS 2.79 vs. 1.91 months. ESR1 testing by liquid biopsy (ctDNA) is now standard after AI progression in the metastatic setting.

Hormone Therapy for Prostate Cancer

Why Androgens Drive Prostate Cancer

Prostate cancer cells express androgen receptor (AR) and require androgens — testosterone and its more potent metabolite dihydrotestosterone (DHT) — to survive and proliferate. Reducing androgens to castrate levels (testosterone <50 ng/dL; ideal <20 ng/dL) induces regression in nearly all treatment-naïve prostate cancers. ADT is the backbone of prostate cancer hormone therapy.

ADT Methods

Method	How It Works	Key Points
GnRH agonists (leuprolide, goserelin)	Initial LH surge → testosterone flare → then sustained castration	Monthly/3-monthly/annual injections; need anti-androgen flare protection in high-risk patients (bicalutamide 2–4 wks)
GnRH antagonists (degarelix, relugolix)	Directly block GnRH receptors → no testosterone flare; faster suppression	Degarelix: monthly SC injection. Relugolix: oral daily; HERO trial: 96.7% castration rate; fewer CV events (preferred for patients with CV disease)
Bilateral orchiectomy	Surgical removal of both testes → immediate, permanent castration	Lowest ongoing cost; used when compliance or immediate response is critical; irreversible

Testosterone Flare — Flare Protection Required in High-Risk Patients

GnRH agonists (leuprolide, goserelin) cause an initial testosterone surge lasting 1–2 weeks before castration occurs. In patients with extensive bone metastases, spinal cord involvement, or urinary obstruction, this flare can cause sudden worsening of pain, paralysis, or urinary retention. In these patients, start anti-androgen coverage (bicalutamide 50 mg/day) 1–2 weeks before the first GnRH agonist injection and continue for 2–4 weeks. GnRH antagonists (degarelix, relugolix) cause no flare and are preferred in this setting.

Novel Anti-Androgens (NHA) — Second-Generation AR Inhibitors

Novel anti-androgens block the androgen receptor more completely than first-generation agents — no agonist activity, they also block AR nuclear translocation and DNA binding:

Enzalutamide (Xtandi): PREVAIL: pre-chemo mCRPC OS 35.3 vs. 31.3 months; ENZAMET/ARCHES: OS benefit added to ADT for mHSPC; PROSPER: nmCRPC MFS 36.6 vs. 14.7 months. Can cause fatigue, falls risk, rarely seizures.
Abiraterone (Zytiga): CYP17A1 inhibitor blocking adrenal and intratumoral androgen synthesis; requires concurrent prednisone 5 mg BID to suppress mineralocorticoid excess. AA-302: mCRPC OS 34.7 vs. 30.3 months; LATITUDE/STAMPEDE: mHSPC OS benefit.
Darolutamide (Nubeqa): Low CNS penetration → minimal fatigue, falls, cognitive effects vs. enzalutamide; ARAMIS: nmCRPC MFS 40.4 vs. 18.4 months; ARASENS: darolutamide + ADT + docetaxel vs. ADT + docetaxel for mHSPC: OS HR 0.68.
Apalutamide (Erleada): SPARTAN: nmCRPC MFS 40.5 vs. 16.2 months; TITAN: mHSPC OS benefit with ADT.

Prostate Cancer Setting	Standard Approach	Key Trial
High-risk localized	RT + 18–36 months ADT	EORTC 22961, RTOG 9413
nmCRPC (PSA rising, no mets)	Enzalutamide OR apalutamide OR darolutamide + continued ADT	PROSPER, SPARTAN, ARAMIS
mHSPC (metastatic, castration-sensitive)	ADT + enzalutamide OR apalutamide OR abiraterone (± docetaxel for high-volume)	ENZAMET, TITAN, LATITUDE, ARASENS
mCRPC	Continue ADT + NHA (if not prior); PARP inhibitor for BRCA1/2-mutated; Lu-177 PSMA post-NHA and post-taxane	PROfound (olaparib), VISION (Lu-PSMA)

hormone therapy cancer ADT prostate cancer breast cancer treatment — Hormone therapy for cancer targets the hormonal signals — estrogen in breast cancer, androgens in prostate cancer — that cancer cells require to grow and survive.

Side Effects and Management

Breast Cancer Hormone Therapy Side Effects

Hot flashes: All endocrine therapies; use venlafaxine or oxybutynin — NOT paroxetine or fluoxetine with tamoxifen (CYP2D6 inhibition). Gabapentin as alternative.
Vaginal dryness / atrophic vaginitis: AI-induced; low-dose topical vaginal estradiol (minimal systemic absorption; discuss with oncologist for adjuvant BC), ospemifene, non-hormonal lubricants
AI arthralgia/myalgia: 30–40% of women; NSAIDs, vitamin D, graded exercise, acupuncture; switching to a different AI may help; consider switching to tamoxifen if fully intolerable and appropriate
Bone density loss: All endocrine therapies; baseline DEXA; vitamin D + calcium; bisphosphonate (zoledronic acid q6m or annual, alendronate weekly oral) or denosumab 60 mg q6m for T-score ≤-2.0
Endometrial cancer (tamoxifen only): Annual gynecologic exam; report abnormal bleeding immediately; no tamoxifen-related GYN risk with AIs
VTE (tamoxifen): ~2× increased risk; minimize concurrent VTE risk factors; if VTE occurs, switch to AI

Prostate Cancer ADT Side Effects

Hot flashes: ~70% of men on ADT; venlafaxine, oxybutynin, gabapentin; megestrol acetate short-term
Sexual dysfunction: Loss of libido (~90%), erectile dysfunction; PDE5 inhibitors (sildenafil, tadalafil) have limited but real benefit; vacuum erectile device; penile rehabilitation program
Bone density loss: Testosterone-dependent bone maintenance lost; denosumab 60 mg q6m reduces vertebral fractures (HALT trial); baseline DEXA and monitoring every 1–2 years; weight-bearing exercise
Metabolic syndrome: Weight gain (visceral fat), insulin resistance, diabetes, dyslipidemia; monitor glucose/HbA1c and lipids; diet and resistance + aerobic exercise most effective intervention
Cardiovascular: GnRH agonists associated with increased MI, stroke, sudden cardiac death; relugolix may have cardiovascular advantage (HERO: 3.8% lower major CV event rate); aggressive CV risk factor management
Fatigue: Most common debilitating side effect; resistance + aerobic exercise programs: strongest evidence-supported intervention (ACSM guidelines)
Gynecomastia: ~50% on long-term ADT; prevent with single-dose prophylactic breast irradiation or tamoxifen 20 mg daily
Anemia: Normocytic; from testosterone-dependent erythropoiesis suppression; check CBC; usually mild

Frequently Asked Questions

What is hormone therapy for cancer?

Hormone therapy for cancer is a systemic treatment that disrupts the hormone signals certain cancers — primarily HR+ breast cancer and prostate cancer — depend on to grow. It works by reducing hormone production (aromatase inhibitors block estrogen synthesis; GnRH agonists/antagonists suppress testosterone), blocking the hormone receptor (tamoxifen, enzalutamide, bicalutamide), or degrading the receptor itself (SERDs: fulvestrant, elacestrant). It is distinct from chemotherapy (which kills any rapidly dividing cell) and targeted therapy (which blocks specific molecular mutations). According to the National Cancer Institute, hormone therapy is used to treat breast cancer, prostate cancer, uterine cancer, and adrenal gland tumors. It is also important not to confuse cancer hormone therapy with hormone replacement therapy (HRT) — they have opposite effects on hormone levels in the body.

How does hormone therapy for breast cancer work?

Hormone receptor-positive breast cancer cells express estrogen receptors (ER) and/or progesterone receptors (PR) that, when activated by estrogen, drive cell proliferation. Hormone therapy disrupts this signal: tamoxifen competitively binds ER in breast tissue (antagonist); aromatase inhibitors (anastrozole, letrozole, exemestane) block estrogen production in postmenopausal women; SERDs (fulvestrant, elacestrant) bind and degrade the ER protein directly. For premenopausal women, ovarian function suppression (GnRH agonists or oophorectomy) brings estrogen to postmenopausal levels, enabling AI use. The ATLAS trial (Lancet 2012) showed that 10 years of adjuvant tamoxifen reduces breast cancer recurrence by 25% and mortality by 29% in years 5–14 compared to 5 years — establishing 10 years as the standard for high-risk HR+ disease. According to the American Cancer Society, most women with HR+ breast cancer will receive some form of hormone therapy as part of their treatment.

What is androgen deprivation therapy (ADT) for prostate cancer?

Androgen deprivation therapy (ADT) reduces testosterone to castrate levels (<50 ng/dL, ideally <20 ng/dL) to deprive prostate cancer cells of their growth signal. ADT is achieved by medical castration: GnRH agonists (leuprolide, goserelin — monthly to annual injections) or GnRH antagonists (degarelix injection or oral relugolix — no testosterone flare; preferred for patients with cardiovascular disease); or surgical castration (bilateral orchiectomy). Novel anti-androgens (enzalutamide, abiraterone, darolutamide, apalutamide) are added to ADT for advanced or castration-resistant disease and significantly extend survival. The HERO trial (Shore ND et al., NEJM 2020) showed oral relugolix achieved 96.7% castration rate with fewer cardiovascular events than standard leuprolide. The Prostate Cancer Foundation provides detailed patient information on ADT options and side effects.

What are the side effects of hormone therapy?

Side effects differ between breast cancer and prostate cancer hormone therapy. For breast cancer: tamoxifen causes hot flashes, vaginal discharge, VTE risk, and endometrial cancer risk (annual GYN exam required); aromatase inhibitors cause arthralgia/myalgia (30–40%), vaginal dryness, and bone density loss (DEXA monitoring + bisphosphonate or denosumab for significant loss); all endocrine therapies cause fatigue and mood changes. For prostate cancer ADT: hot flashes (~70%), loss of libido (~90%), erectile dysfunction, bone density loss (denosumab), metabolic syndrome (weight gain, insulin resistance), cardiovascular risk increase with GnRH agonists, fatigue (exercise programs are most evidence-supported), and gynecomastia (~50% on long-term ADT). Most side effects are manageable — bone density loss, hot flashes, metabolic effects, and gynecomastia all have effective prevention and treatment strategies. Discuss expected side effects specific to your drug and duration with your oncology team before starting.

How long does hormone therapy last?

Duration depends on cancer type and stage. For HR+ early breast cancer: adjuvant hormone therapy typically continues 5–10 years — the ATLAS trial showed that 10 years of tamoxifen reduces recurrence by 25% and mortality by 29% vs. 5 years; NCCN recommends 10 years total endocrine therapy for high-risk disease. For metastatic HR+ breast cancer: hormone therapy continues until disease progression or unacceptable toxicity. For prostate cancer: in metastatic hormone-sensitive disease, ADT is typically continuous and long-term. For non-metastatic biochemical recurrence or certain castration-sensitive settings, intermittent ADT (stopping when PSA reaches nadir, restarting when PSA rises above threshold) provides equivalent oncologic outcomes with improved quality of life during the off-periods — SEIDO trial and meta-analyses support this for appropriate patients. In castration-resistant prostate cancer, ADT continues indefinitely (maintain castrate levels) while additional agents are layered on top.

Does hormone therapy cause menopause?

For premenopausal women with breast cancer: GnRH agonists (goserelin, leuprolide) temporarily suppress ovarian function — causing hot flashes, vaginal dryness, irregular periods, and other menopausal symptoms for as long as they are taken; ovarian function typically recovers within 6–18 months after stopping (though recovery varies with age and prior chemotherapy). Surgical oophorectomy causes permanent surgical menopause. Tamoxifen can cause menopausal symptoms (hot flashes, vaginal changes) but does not suppress ovarian function directly. Aromatase inhibitors cannot cause menopause in premenopausal women — premenopausal ovaries would simply produce more estrogen to compensate; AIs only work when estrogen levels are already low. For postmenopausal women, AIs, tamoxifen, and SERDs worsen already-present menopausal symptoms but don’t cause menopause. For men on ADT: testosterone suppression causes an andropause-like syndrome — hot flashes, mood changes, bone loss, fatigue, and sexual dysfunction — analogous to menopause in women and managed with similar strategies. See the cancer diagnosis questions guide for what to ask your team before starting hormone therapy.

Davies C et al. — ATLAS trial (10 vs. 5 yr tamoxifen); Lancet 2012
Pagani O et al. — SOFT/TEXT trials (OFS + exemestane premenopausal HR+ BC); 8-yr follow-up ASCO 2019
Baum M et al. / Forbes JF et al. — ATAC trial (anastrozole vs. tamoxifen adjuvant); Lancet 2002; 10-yr update 2008
Robertson JF et al. — FALCON trial (fulvestrant vs. anastrozole MBC); Lancet 2016
Bidard FC et al. — EMERALD trial (elacestrant ESR1-mutated MBC); JCO 2022
Shore ND et al. — HERO trial (relugolix vs. leuprolide prostate cancer); NEJM 2020
Fizazi K et al. / Smith MR et al. — ARAMIS (darolutamide nmCRPC); NEJM 2019; OS 2022
Smith MR et al. — ARASENS (darolutamide + ADT + docetaxel mHSPC); NEJM 2022
Beer TM et al. — PREVAIL (enzalutamide mCRPC); NEJM 2014
Ryan CJ et al. — AA-302 (abiraterone + prednisone mCRPC); NEJM 2013
Smith MR et al. — HALT trial (denosumab for bone density in ADT-treated men); NEJM 2009
National Cancer Institute — Hormone Therapy to Treat Cancer
American Cancer Society — Hormone Therapy for Breast Cancer
Prostate Cancer Foundation — Hormonal Therapy for Prostate Cancer

This article is for educational purposes only and does not constitute medical advice. Discuss all hormone therapy decisions with your oncology care team.